CClinicalTrials.gg
Sign In
Not yet recruitingNCT07423481SEMAFOLLOWUpdated Sep 18, 2026

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

An observational study in Obesity & Overweight, sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Nantes University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Study summary

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

02

Conditions studied

  • Obesity & Overweight

Keywords

  • WEGOVY®
  • sémaglutide 2,4 mg
  • Obesity
  • Overweight
  • ATU
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated with WEGOVY® (semaglutide 2.4 mg) under temporary authorization for use (ATU) and the early access program in France.

Inclusion criteria

  • Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
  • No objection to the use of their data
  • Patients able to complete an online questionnaire (via the internet)

Exclusion criteria

Exclusion Criteria:

  • Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • SEMAFOLLOW study population

    Patient agreeing to participate in the SEMAFOLLOW study.

    Other: SEMAFOLLOW questionnaire

Interventions

  • OtherSEMAFOLLOW questionnaire

    If the patient agrees, the center will send a link to the questionnaires via email. Patients who have completed the questionnaires will be analyzed in the SEMAFOLLOW study. Estimated time to complete the questionnaire: approximately 30 minutes

05

What researchers measure

Primary outcomes

  1. Describe weight changes during the follow-up period according to patient characteristics.

    Time frame: Baseline

Secondary outcomes

  1. Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.

    Time frame: Baseline

  2. Compare the profiles of responders and non-responders

    Time frame: Baseline

  3. Describe weight change according to different subpopulations.

    Time frame: Baseline

06

Study locations

1 site
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07423481
Lead sponsor
Nantes University Hospital
Collaborators
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

David JACOBI
Contact
David.Jacobi@univ-nantes.fr
+332 53 48 28 35
David JACOBI
study director · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obesity→

Other studies from this sponsor

Nantes University Hospital

Start the discussion